报价延迟最少15分钟:2025/09/17 18:32 EDT
盘后时段
|
||||
|
6.44 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.21
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.20/-3.20
|
|
企业价值
113.72M
|
| 资产负债 |
|
每股账面净值
0.14
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
71.32M
|
|
每股收益
5.50
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/17 18:32 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. |
